⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer

Official Title: Phase 2 Study of HKI-272 In Subjects With Advanced Breast Cancer

Study ID: NCT00300781

Interventions

neratinib

Study Description

Brief Summary: The purpose of this study is to learn whether neratinib is safe and effective in treating women with advanced human epidermal growth factor receptor 2 (HER2) positive breast cancer.

Detailed Description: Arm A: HER2 gene amplification and disease progression following at least 6 weeks of standard doses of Herceptin; Arm B: HER2 gene amplification and no prior Herceptin or HER2-targeted treatment.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

University of Colorado Hospital, Aurora, Colorado, United States

Midwestern Regional Medical Center, Zion, Illinois, United States

Louisiana State University, Shreveport, Louisiana, United States

The Cancer Center at GBMC, Baltimore, Maryland, United States

Oncology Care Associates, Bethesda, Maryland, United States

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Boston University Medical Center, Boston, Massachusetts, United States

Faulkner Hospital, Boston, Massachusetts, United States

Norris Cotton Cancer Center Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States

The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

The Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States

Virginia Mason Medical Center, Seattle, Washington, United States

Institut Jules Bordet Unite du Chimiotherapie, Brussels, , Belgium

University Hospital Gasthuisberg, Leuven, , Belgium

St-Augustinus Ziekenhuis Oncology Department, Wilrijk, , Belgium

The Hospital Affiliated Academy Military Medical Science, Chinese People's Liberation Army, Beijing, Beijing, China

No. 81 Hospital of Chinese People's Liberation Army, Nanjing, Jiangsu, China

Cancer Hospital Peking Union Medical College, Beijing, , China

Chinese People's Liberation Army General Hospital, Beijing, , China

Institut Gustave ROUSSY Service de Pathologie Mammaire, Villejuif Cedex, , France

Jehangir Clinical Development Centre, Pune, Maharashtra, India

Deenanath Mangeshkar Hospital, Pune, Maharashtra, India

Nizam's Institute of Medical Sciences, Hyderabad, Panjagutta, India

Tata Memorial Centre, Mumbai, Parel, India

Hospital Regional Lic. Adolfo Lopez Mateos Oncología Médica, Mexico City, , Mexico

Arke Estudios Clínicos S.A. de C.V., Mexico City, , Mexico

Hospital de Especialidades MIG, Mexico City, , Mexico

N.N. Blokhin Russian Cancer Research Center of RAMS, Moscow, , Russian Federation

Medical Radiological Research Center of RAMS, Department of Radiation and Surgical Methods, Obninsk, , Russian Federation

City Oncology Dispensary, Saint Petersburg, , Russian Federation

City Hospital N 31 Oncology Haematology Dept. For Adults, Saint Petersburg, , Russian Federation

Breast Tumor Department, N.N. Petrov Research Institute of Oncology, Saint-Petersburg, , Russian Federation

Contact Details

Name: Puma

Affiliation: Biotechnology

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: